 The FDA has instituted a clinical hold on Foghorn Therapeutics Incs NASDAQ: FHTX Phase 1 dose-escalation study of FHD-286 in relapsed andor refractory acute myelogenous leukemia AML and myelodysplastic syndrome MDS. The FDA initiated the partial clinical hold. 